Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study

Gowri Satyanarayana
Kyle T Enriquez
Tianyi Sun
Elizabeth J Klein
Maheen Abidi

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/medoncfp

Part of the Oncology Commons

Let us know how access to this document benefits you

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Authors
Gowri Satyanarayana, Kyle T Enriquez, Tianyi Sun, Elizabeth J Klein, Maheen Abidi, Shailesh M Advani, Joy Awosika, Ziad Bakouny, Babar Bashir, Stephanie Berg, Marilia Bernardes, Pamela C Egan, Arielle Elkrief, Lawrence E Feldman, Christopher R Friese, Shipra Goel, Cyndi Gonzalez Gomez, Keith L Grant, Elizabeth A Griffiths, Shuchi Gulati, Shilpa Gupta, Clara Hwang, Jayanshu Jain, Chinmay Jani, Anna Kaltsas, Anup Kasi, Hina Khan, Natalie Knox, Vadim S Koshkin, Daniel H Kwon, Chris Labaki, Gary H Lyman, Rana R McKay, Christopher McNair, Gayathri Nagaraj, Elizabeth S Nakasone, Ryan Nguyen, Taylor K Nonato, Adam J Olszewski, Orestis A Panagiotou, Matthew Puc, Pedram Razavi, Elizabeth V Robilotti, Miriam Santos-Dutra, Andrew L Schmidt, Dimpy P Shah, Sumit A Shah, Kendra Vieira, Lisa B Weissmann, Trisha M Wise-Draper, Ulysses Wu, Julie Tsu-Yu Wu, Toni K Choueiri, Sanjay Mishra, Jeremy L Warner, Benjamin French, and Dimitrios Farmakiotis
Background. The frequency of coinfections and their association with outcomes have not been adequately studied among patients with cancer and coronavirus disease 2019 (COVID-19), a high-risk group for coinfection.

Methods. We included adult (≥18 years) patients with active or prior hematologic or invasive solid malignancies and laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection, using data from the COVID-19 and Cancer Consortium (C3CC19, NCT04354701). We captured coinfections within ±2 weeks from diagnosis of COVID-19, identified factors cross-sectionally associated with risk of coinfection, and quantified the association of coinfections with 30-day mortality.

Results. Among 8765 patients (hospitalized or not; median age, 65 years; 47.4% male), 16.6% developed coinfections: 12.1% bacterial, 2.1% viral, 0.9% fungal. An additional 6.4% only had clinical diagnosis of a coinfection. The adjusted risk of any coinfection was positively associated with age ≥50 years, male sex, cardiovascular, pulmonary, and renal comorbidities, diabetes, hematologic malignancy, multiple malignancies, Eastern Cooperative Oncology Group Performance Status, progressing cancer, recent cytotoxic chemotherapy, and baseline corticosteroids; the adjusted risk of superinfection was positively associated with tocilizumab administration. Among hospitalized patients, high neutrophil count and C-reactive protein were positively associated with bacterial coinfection risk, and high or low neutrophil count with fungal coinfection risk. Adjusted mortality rates were significantly higher among patients with bacterial (odds ratio [OR], 1.61; 95% CI, 1.33–1.95) and fungal (OR, 2.20; 95% CI, 1.28–3.76) coinfections.

Conclusions. Viral and fungal coinfections are infrequent among patients with cancer and COVID-19, with the latter associated with very high mortality rates. Clinical and laboratory parameters can be used to guide early empiric antimicrobial therapy, which may improve clinical outcomes.

Keywords. bacterial infections; CAPA (COVID-19-associated pulmonary aspergillosis); COVID-19; mucormycoses; viral infections.

Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), has infected >288 million people and contributed to >5.4 million deaths globally [1]. Among patients with confirmed COVID-19, the frequency of cancer diagnosis has been reported to be 2% [2]. Nevertheless, large meta-analyses of patients with cancer and COVID-19 have described mortality rates of 19%–23% and a case fatality rate (CFR) of 23% [2, 3]. Converstly, patients without cancer with COVID-19 had 3-fold lower odds of mortality and a CFR of only 6% [2, 3]. Patients
with cancer hospitalized for management of COVID-19 have a >40% risk of developing severe illness [2].

Critical illness with interventions such as the placement of central venous access catheters and endotracheal tubes and shifts in the immune profile during COVID-19 might lead to the development of a coinfection [4]. Treatment modalities for COVID-19, including steroids and other immune-modulating therapies, such as interleukin 6 (IL6) inhibitors (eg, tocilizumab), can increase the risk of development of secondary infections. Several studies have described coinfections among patients with COVID-19. Meta-analyses have found bacterial infection rates of 3.5%–7% on initial presentation and 14.3% for secondary bacterial infection [5, 6]. A systematic review of 9 studies reporting coinfections among patients with COVID-19 showed that 8% of patients developed a bacterial or fungal coinfection [7].

Patients with cancer are vulnerable to infection due to myelosuppression and other forms of direct immune suppression caused by cytotoxic chemotherapy or chronic steroids, side effects of chemotherapy on mechanical barriers (eg, mucositis and skin ulceration), presence of indwelling central venous catheters, and increased exposure to health care facilities [8]. One study of 684 patients with cancer focused on coinfections showed higher incidence compared with the general population [5–7, 9].

In this study, we captured bacterial, fungal, and viral coinfections in a large multi-institutional cohort of patients with cancer and COVID-19, identified factors associated with an increased risk of such coinfections, and quantified the association of coinfections with 30-day all-cause mortality.

METHODS

Study Design

The COVID-19 and Cancer Consortium (CCC19) is an international registry that includes reports of >12,000 patients with current or historical cancer diagnoses who developed presumed or laboratory-confirmed COVID-19. The registry was built by and is maintained at Vanderbilt University Medical Center (VUMC) [10]. One hundred twenty-nine participating sites from the United States, Mexico, and Canada independently identify patients and report data through electronic REDCap survey instruments developed by CCC19. The mechanism of data collection can be retrospective (after the course of COVID-19) or concurrent at the discretion of the respondent. To ensure that data are high quality, each report is reviewed centrally and assigned a quality score, as previously described [10].

This was a retrospective cohort study with cross-sectional analyses (except for mortality analysis). We included adult (≥18 years) patients with a laboratory-confirmed diagnosis of SARS-CoV-2 infection, regardless of hospitalization status. We excluded reports with inadequate data quality (>4 according to our previously published metric), those with noninvasive cancers, premalignant conditions, nonmelanoma skin cancers, and those with unknown coinfection status or 30-day mortality [10]. Patients who were not admitted to the hospital were excluded from analyses that included laboratory values, because laboratory values were uncommonly reported among outpatients.

Procedures and Outcome Definitions

Day of COVID-19 diagnosis (baseline) was defined as the day the first positive PCR test was collected. The primary end point was any non-SARS-CoV-2 infection diagnosed with positive microbiological tests and/or compatible clinical picture (eg, chest imaging with superimposed pneumonia, not due to COVID-19 alone per clinician assessment), as explained below. All coinfections studied within this cohort were reported to have been within ±2 weeks of COVID-19 diagnosis. Coinfection data were either reported via a structured data field or interpreted from de-identified free-text responses provided by sites for each patient at the time of data entry, with queries sent to individual sites for clarification when appropriate (full data dictionary available at: https://github.com/covidncancer/CCC19_dict).

Secondary end points were bacterial, viral, and fungal coinfections. In a separate outcome analysis, we evaluated the association between coinfection and all-cause mortality within 30-days after COVID-19 diagnosis.

Covariates

Clinically relevant variables included in this study were age, sex, race and ethnicity, time of COVID-19 diagnosis, geographical region of patient residence, smoking status, obesity, comorbid conditions (cardiovascular, pulmonary, renal disease, diabetes), Eastern Cooperative Oncology Group (ECOG) Performance Status, type of malignancy (solid or hematological), cancer status (remission or active [measurable] disease, with active further classified as stable, responding to treatment, or progressing), anticancer therapy, and COVID-19 treatments. Active anticancer therapy was classified as either cytotoxic chemotherapy or all other therapies except surgery (targeted drugs, endocrine therapy, immunotherapy, radiotherapy) given before COVID-19 diagnosis [10].

We could not determine whether corticosteroids initiated after diagnosis of COVID-19 for treatment of COVID-19 were administered before or after coinfection onset. Therefore, we only studied baseline corticosteroids (preceding COVID-19 diagnosis, which the patients were taking for reasons other than COVID-19). Nevertheless, we examined the cross-sectional association between tocilizumab use as treatment for COVID-19 and superinfections, given that active infection is a contraindication to tocilizumab administration [11]. Therefore, it is highly unlikely that tocilizumab was administered after diagnosis of an infection other than COVID-19, and any coinfections were in all likelihood diagnosed after administration of tocilizumab.
Statistical Methods
All analysis methods were prespecified in a statistical analysis plan before initiation of the analysis (included with variable list as Supplementary Data). We used descriptive statistics to compare baseline characteristics between patients with and without any coinfection, both overall and among patients who were hospitalized for any reason at the time of COVID-19 diagnosis. Adjusted cross-sectional associations between these characteristics and the odds of any coinfection, as well as bacterial, viral, and fungal coinfections, were estimated from multivariable logistic regression models and represented as odds ratios (ORs) and 95% CIs. Logistic regression models also quantified the adjusted association of coinfection (any, bacterial, viral, fungal, and not classified [clinical only diagnosis]) with 30-day mortality. Adjustment variables were selected a priori based on clinical knowledge (Table 2; Supplementary Table 2); no statistical model selection procedures were used.

Exploratory analyses with smoothing splines were used to determine the association of age (as a continuous variable) with outcomes; regression splines were used to model apparent nonlinear associations. For analyses of any coinfection and bacterial coinfections, there were sufficient degrees of freedom to include all prespecified variables. For analyses of viral and fungal coinfections, model degrees of freedom were limited by the low number of events. We therefore used a reduced set of variables considered to be most clinically relevant (Table 1; Supplementary Table 1). Model stability was assessed by comparing adjusted and unadjusted regression coefficients and their standard errors, as well as variance inflation factors.

Multiple imputation (10 iterations) using additive regression, bootstrapping, and predictive mean matching was used to impute missing and unknown data, except unknown ECOG Performance Status and unknown cancer status, which were not imputed and included as “unknown” categories. Imputation was performed on the full data set (n = 8765). A separate imputation model (20 iterations) was developed for laboratory values among hospitalized patients (n = 4508). All analyses were performed in R, version 4.0.4 (R Foundation for Statistical Computing, Vienna, Austria), including the rms extension package.

Role of the Funding Source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or manuscript preparation. The corresponding author had full access to aggregate data in the study and had final responsibility for the decision to submit for publication.

RESULTS

Patient Cohort
Of 12,034 reports in the registry at the time of data lock (6/6/2021), 8765 met inclusion criteria (Figure 1).

### Table 1. Baseline Demographic and Clinical Characteristics Stratified by Diagnosis of any Coinfection

|                                 | Any Coinfection (n = 1458), No. (%) | No Coinfection (n = 7308), No. (%) |
|---------------------------------|-------------------------------------|-----------------------------------|
| Age (median, IQR, y)            | 69.0 (60.0–78.0)                    | 64.0 (54.0–74.0)                  |
| Sex                             |                                     |                                   |
| Female                          | 676 (46.3)                          | 3925 (53.7)                       |
| Male                            | 781 (53.5)                          | 3376 (46.2)                       |
| Missing/unknown                 | 2 (0.1)                             | 5 (0.1)                           |
| Race/ethnicity                  |                                     |                                   |
| Non-Hispanic White              | 791 (54.2)                          | 3866 (52.9)                       |
| Non-Hispanic Black              | 276 (18.9)                          | 1340 (18.3)                       |
| Hispanic                        | 232 (15.9)                          | 1150 (15.7)                       |
| Other                           | 144 (9.9)                           | 827 (11.3)                        |
| Missing/unknown                 | 16 (1.1)                            | 123 (1.7)                         |
| Region                          |                                     |                                   |
| Northeast                       | 685 (46.9)                          | 2465 (33.7)                       |
| Midwest                         | 332 (22.8)                          | 2033 (27.8)                       |
| South                           | 177 (12.1)                          | 1120 (15.3)                       |
| West                            | 185 (12.7)                          | 1393 (19.1)                       |
| Undesignated                    | 10 (0.7)                            | 0 (0.0)                           |
| Non-US                          | 70 (4.8)                            | 295 (4.0)                         |
| Smoking status                  |                                     |                                   |
| Never smoked                    | 688 (47.2)                          | 3964 (54.3)                       |
| Former smoker                   | 659 (45.2)                          | 2693 (36.9)                       |
| Current smoker                  | 54 (3.7)                            | 438 (6.0)                         |
| Missing/unknown                 | 58 (4.0)                            | 211 (2.9)                         |
| Obesity                         |                                     |                                   |
| No                              | 932 (63.9)                          | 4471 (61.2)                       |
| Yes                             | 526 (36.1)                          | 2796 (38.3)                       |
| Missing/unknown                 | 1 (0.1)                             | 39 (0.5)                          |
| Comorbid conditions             |                                     |                                   |
| Diabetes                        | 502 (34.4)                          | 1830 (25.0)                       |
| Pulmonary disease               | 376 (25.8)                          | 1364 (18.7)                       |
| Cardiovascular disease          | 582 (39.9)                          | 1966 (26.8)                       |
| Renal disease                   | 320 (21.9)                          | 942 (12.9)                        |
| Missing/unknown                 | 4 (0.3)                             | 62 (0.8)                          |
| ECOG Performance Status         |                                     |                                   |
| 0                               | 310 (21.2)                          | 2579 (35.3)                       |
| 1                               | 378 (25.9)                          | 1871 (25.6)                       |
| 2+                              | 324 (22.2)                          | 894 (12.2)                        |
| Unknown                         | 445 (30.5)                          | 1956 (26.8)                       |
| Missing                         | 2 (0.1)                             | 7 (0.1)                           |
| Type of malignancy              |                                     |                                   |
| Solid tumor                     | 1113 (76.3)                         | 5973 (81.8)                       |
| Hematological neoplasm          | 417 (28.6)                          | 1567 (21.4)                       |
| Cancer status                   |                                     |                                   |
| Remission/NED                   | 640 (43.9)                          | 3522 (48.2)                       |
| Stable/responding               | 370 (25.4)                          | 2218 (30.4)                       |
| Progressing                     | 264 (18.1)                          | 918 (12.6)                        |
| Unknown                         | 185 (12.7)                          | 645 (8.8)                         |
| Missing                         | 0 (0.0)                             | 3 (0.0)                           |
| HCT                             |                                     |                                   |
| No                              | 1449 (99.3)                         | 7267 (99.5)                       |
| Yes                             | 10 (0.7)                            | 38 (0.5)                          |
| Missing/unknown                 | 0 (0.0)                             | 1 (0.0)                           |
| Recent cytotoxic chemotherapy   |                                     |                                   |
| Never/beyond 12 mo              | 1015 (69.6)                         | 5453 (74.6)                       |
| Within 4 wk                     | 275 (18.8)                          | 1129 (15.5)                       |
Table 1. Continued

| Period of COVID-19 diagnosis | Any Coinfection (n = 1459), No. (%) | No Coinfection (n = 7306), No. (%) |
|-----------------------------|-----------------------------------|-----------------------------------|
| 4 wk to 3 mo                | 64 (4.4)                          | 252 (3.4)                         |
| 3 to 12 mo                  | 40 (2.7)                          | 247 (3.4)                         |
| Missing/Unknown             | 65 (4.5)                          | 225 (3.1)                         |
| Baseline corticosteroids    |                                   |                                   |
| No                          | 1102 (75.5)                       | 6152 (84.2)                       |
| Yes                         | 325 (22.3)                        | 1012 (13.9)                       |
| Missing/Unknown             | 32 (2.2)                          | 142 (1.9)                         |
| Tocilizumab                 |                                   |                                   |
| No                          | 1326 (90.9)                       | 6971 (95.4)                       |
| Yes                         | 99 (6.8)                          | 121 (1.7)                         |
| Missing/Unknown             | 34 (2.3)                          | 214 (2.9)                         |

Adjusted cross-sectional associations of clinical or treatment factors and coinfections are summarized in Table 2 and Figure 2 for all patients and in Supplementary Table 2 for hospitalized patients only. Clinical types of coinfections are summarized in Supplementary Table 3.

Risk of any coinfection was positively associated with age among patients >50 years, male sex, cardiovascular, pulmonary, or renal comorbid conditions, diabetes, ECOG Performance Status, hematologic malignancy, multiple malignancies, progressing or unknown cancer status, cytotoxic chemotherapy within 4 weeks before COVID-19 diagnosis, baseline corticosteroids, tocilizumab administration, and COVID-19 diagnosis between May and August 2020.

A majority of the above factors showed strong associations of similar magnitude with the risk of bacterial coinfections. The risk for viral coinfection was positively associated with pulmonary disease, diabetes, hematologic malignancy, multiple malignancies, baseline corticosteroids, and diagnosis of COVID-19 between May and August 2020. Fungal coinfections were associated with cytotoxic chemotherapy last given between 3 months and 4 weeks before COVID-19 diagnosis and tocilizumab administration.

Among hospitalized patients, high C-reactive protein (CRP) was associated with higher risk of any coinfection, and high neutrophil count was associated with higher risk of bacterial or fungal coinfection. Neutropenia was associated with higher risk of fungal coinfection. Lymphopenia was not associated with risk of coinfection.

Mortality

All-cause 30-day mortality was significantly higher among patients with any (23.8%), bacterial (24.6%), and viral (22.9%) coinfections compared with all other patients (9.4%, 10.1%, and 11.6%, respectively) and >2-fold higher among patients with fungal coinfections (34.2%), compared with all other patients (11.6%) (Figure 3). Adjusted 30-day all-cause mortality rates were markedly higher among patients with any, bacterial, and especially fungal coinfections, compared with those without the respective coinfections (Table 3).

DISCUSSION

We identified factors associated with coinfection among 8765 patients with cancer and COVID-19. Laboratory values such as high neutrophil count may be useful in differentiating bacterial or fungal coinfection from COVID-19 alone. Neutropenia was associated with fungal coinfections, which were overall rare. Development of any, but especially fungal coinfection, was associated with higher adjusted all-cause mortality compared with patients without coinfection. Tocilizumab administration exhibited a strong association with development of bacterial and fungal superinfection.

Infection remains a leading cause of mortality among immunocompromised patients, including those with malignancies [8]. Many more patients with cancer die from infection, compared with the general population [12]. Patients with cancer and COVID-19 are subject to immune modulation through treatments for cancer (eg, chemotherapy-induced myelosuppression, administration of corticosteroids for antineoplastic or supportive purposes) and for COVID-19 infection (eg, corticosteroids, IL6 inhibitors). Furthermore, SARS-CoV-2 has been implicated as an immunomodulating virus, causing a maladaptive immune response [4].

The percentage of coinfections in immunocompromised patients with COVID-19 has been previously reported to be as high as 60% among transplant recipients [13]. In another recent study of patients with underlying malignancies or organ...
Table 2. Adjusted Associations of Baseline Factors With Concomitant Infection Among all Patients

| Table 2. Adjusted Associations of Baseline Factors With Concomitant Infection Among all Patients |
|---------------------------------------------------------------|
| **Age**                                                      |
| ≤50 (per decade increase) 1.02 (0.88–1.18)                    |
| >50 (per decade increase) 1.14 (1.07–1.21)                    |
| **Sex**                                                      |
| Female Ref                                                     |
| Male 1.23 (1.08–1.38)                                         |
| **Race/ethnicity**                                           |
| Non-Hispanic White Ref                                        |
| Non-Hispanic Black 0.97 (0.82–1.14)                           |
| Hispanic 1.09 (0.91–1.31)                                    |
| Other 0.83 (0.67–1.03)                                        |
| **Region**                                                   |
| Northeast Ref                                                 |
| Midwest 0.68 (0.58–0.79)                                      |
| South 0.71 (0.58–0.86)                                        |
| West 0.60 (0.50–0.73)                                         |
| Non-US 1.12 (0.82–1.53)                                      |
| **Smoking status**                                           |
| Never smoked Ref                                              |
| Former smoker 1.08 (0.95–1.23)                               |
| Current smoker 0.65 (0.48–0.89)                              |
| **Obesity**                                                  |
| No Ref                                                        |
| Yes 0.97 (0.85–1.10)                                          |
| **Diabetes**                                                 |
| No Ref                                                        |
| Yes 1.35 (1.18–1.54)                                          |
| **Pulmonary disease**                                        |
| No Ref                                                        |
| Yes 1.27 (1.10–1.47)                                          |
| **Cardiovascular disease**                                   |
| No Ref                                                        |
| Yes 1.22 (1.06–1.40)                                          |
| **Renal disease**                                            |
| No Ref                                                        |
| Yes 1.31 (1.12–1.53)                                          |
| **ECOG Performance Status**                                  |
| 0 Ref                                                         |
| 1 1.30 (1.10–1.55)                                            |
| 2+ 1.95 (1.61–2.37)                                           |
| Unknown 1.60 (1.36–1.90)                                     |
| **Type of malignancy**                                       |
| Solid tumor Ref                                               |
| Hematological neoplasm 1.41 (1.21–1.64)                      |
| Multiple tumors 1.34 (1.12–1.59)                             |
| **Cancer status**                                            |
| Remission/NED Ref                                             |
| Stable/responding 0.78 (0.67–0.91)                           |
| Progressing 1.26 (1.05–1.51)                                 |
| Unknown 1.25 (1.03–1.53)                                     |
| **HCT**                                                      |
| No Ref                                                        |
| Yes 1.22 (0.58–2.57)                                          |
| **Recent cytotoxic chemotherapy**                            |
| Never/beyond 12 mo Ref                                       |
| Within 4 wk 1.35 (1.13–1.60)                                 |

| **Any Coinfection Odds Ratio (95% CI)**                      |
| **Bacterial Coinfection Odds Ratio (95% CI)**                |
| **Viral Coinfection Odds Ratio (95% CI)**                    |
| **Fungal Coinfection Odds Ratio (95% CI)**                   |

| **Age** | 0.94 (0.85–1.05) | 1.00 (0.85–1.18) |
| **Sex** | Ref | Ref |
| **Race/ethnicity** | Ref | Ref | Ref |
| **Region** | Ref | Ref | Ref |
| **Smoking status** | Ref | Ref |
| **Obesity** | Ref | Ref | Ref |
| **Diabetes** | Ref | Ref | Ref |
| **Pulmonary disease** | Ref | Ref | Ref |
| **Cardiovascular disease** | Ref | Ref |
| **Renal disease** | Ref |
| **ECOG Performance Status** | Ref |
| **Type of malignancy** | Ref | Ref | Ref |
| **Cancer status** | Ref | Ref |
| **HCT** | Ref | Ref |
| **Recent cytotoxic chemotherapy** | Ref | Ref | Ref |
| **Within 4 wk** | 1.35 (1.13–1.60) | 1.16 (0.95–1.42) | 0.89 (0.60–1.31) | 1.54 (0.86–2.74) |
transplantation, the cumulative incidence of coinfections was 27% [14]. Most immunosuppressed patients receive empiric antibacterial or antifungal agents, which can lead to high costs, side effects, drug–drug interactions, and development of resistance. In a previous report from Europe, North America, and South America, >80% of patients with cancer and COVID-19 received empiric antimicrobials, although only 8% had another infection at the time of COVID-19 diagnosis, and 19% developed secondary infections [9].

To our knowledge, this is the largest study of coinfections among patients with cancer and COVID-19 to date. Coinfections were reported in 17% of patients with cancer and COVID-19. This proportion is higher than that captured in the general population [7], but still relatively low, and similar to that of a previous report [9]. In that series, most coinfections were bacterial and associated with high CRP levels and increased mortality, in agreement with our results.

Our findings and those of Gudiol et al. indicate that most patients with cancer and COVID-19 do not develop coinfections [9]. However, the high mortality rates associated with coinfections in both reports call for early diagnosis and treatment. Also, like COVID-19 itself, bacterial and fungal infections can add indirectly to cancer-attributable morbidity and mortality by delaying the administration of potentially lifesaving chemotherapy [8]. Thus, we identified clinical parameters (older age, male sex, diabetes, pulmonary, cardiovascular, or renal comorbid conditions, baseline corticosteroids, cytotoxic chemotherapy, performance status, hematologic or multiple malignancies, progressing cancer) and laboratory values (CRP, neutrophil count) that could be useful for risk stratification. For example, neutropenic patients who have received recent cytotoxic chemotherapy or tocilizumab could benefit from preemptive protocols including serial (eg, weekly or twice weekly) testing of fungal markers and early administration of antifungal agents in the setting of worsening pneumonia or sepsis, taking into account regional and institutional epidemiological data.

Given that many factors associated with coinfection were also associated with adverse COVID-19 outcomes in prior studies (eg, older age, male sex, comorbidities), it is likely that coinfections are an important mediator of adverse outcome [15, 16]. However, lymphopenia was not associated with risk of coinfection, although it was strongly associated with severe illness and mortality in previous CCC19 studies [15, 16]. The results of this report merit further external validation and may help develop predictive models to guide timely and appropriate use of antibiotics and promote effective antimicrobial stewardship.

With the large number of mucormycosis cases observed during the SARS-CoV-2 surge in India, post-COVID-19 fungal infections have emerged as an important category of highly lethal coinfections [17]. The fungal syndrome that has been best described is COVID-19-associated pulmonary aspergillosis (CAPA), with small case series reporting frequencies of 20%–30% among patients with severe COVID-19 [18–20]. Unlike post-COVID-19 mucormycosis, where >90% of cases are proven, most cases of CAPA are classified as probable/putative [17, 18]. Notably, a series of postmortem cases and 1 recent systematic review of autopsy data indicate that many cases classified as CAPA reflect colonization with Aspergillus, as proven invasive mold disease was rare (0%–2%), even when studied only among patients with severe COVID-19 who died [21, 22].

Our results support the notion that COVID-19-associated fungal coinfections are rare, as their prevalence was only 0.9%. Likewise, Saade et al. reported only 1 fungal infection among

Table 2. Continued

| Time Period | Any Coinfection Odds Ratio (95% CI) | Bacterial Coinfection Odds Ratio (95% CI) | Viral Coinfection Odds Ratio (95% CI) | Fungal Coinfection Odds Ratio (95% CI) |
|-------------|-----------------------------------|------------------------------------------|--------------------------------------|----------------------------------------|
| 4 wk to 3 mo | 1.28 (0.94–1.73)                  | 1.19 (0.84–1.69)                      | 0.79 (0.37–1.66)                      | 3.08 (1.41–6.70)                       |
| 3 to 12 mo  | 0.90 (0.62–1.29)                  | 0.75 (0.49–1.16)                      | 0.55 (0.20–1.54)                      | 0.93 (0.21–4.03)                       |
| Baseline corticosteroids |                         |                                          |                                      |                                        |
| No          | Ref                               | Ref                                     | Ref                                  | Ref                                    |
| Yes         | 1.39 (1.19–1.62)                  | 1.23 (1.02–1.47)                      | 2.42 (1.75–3.35)                      | 1.40 (0.82–2.40)                       |
| Tocilizumab |                                     |                                          |                                      |                                        |
| No          | Ref                               | Ref                                     | Ref                                  | Ref                                    |
| Yes         | 3.32 (2.48–4.44)                  | 3.61 (2.67–4.87)                      | 1.78 (0.98–3.21)                      | 5.48 (2.72–11.04)                      |
| Period of COVID-19 diagnosis |                     |                                          |                                      |                                        |
| Jan–Apr 2020 | Ref                                | Ref                                    | Ref                                  | -                                      |
| May–Aug 2020 | 1.21 (1.04–1.40)                  | 1.07 (0.90–1.27)                      | 1.62 (1.15–2.29)                      | -                                      |
| Sept–Dec 2020 | 0.87 (0.72–1.05)                  | 1.04 (0.85–1.29)                      | 0.33 (0.17–0.67)                      | -                                      |
| Jan–Apr 2021 | 0.67 (0.54–0.83)                  | 0.73 (0.58–0.93)                      | 0.32 (0.15–0.69)                      | -                                      |
| May–Jun 2021 | 0.96 (0.48–1.93)                  | 1.05 (0.48–2.29)                      | -                                    | -                                      |

Abbreviations: COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; HCT, hematopoietic cell transplant; NED, no evidence of disease.

*Comparison group: Jan–Jun 2021 vs Jan–Apr 2020.

*Satyanarayana et al.
Supplementary Table 1

Invasive fungal infections is elusive, and some cases may not have been captured, especially given the 2-week time frame and long incubation times of mold infections [23]. Unlike some other cohorts, we do not know of standardized diagnostic protocols and surveillance for CAPA across different centers participating in CCC19 [24, 25]. However, these caveats could have been offset by the significant number of patients at risk for invasive fungal infections in our report, such as those with neutropenia (8.7% of patients with coinfections) (Table 1).

Figure 1. Descriptive flowchart of patients included in the study. aNonmelanoma skin cancers, in situ malignancies, or premalignant conditions. bDuplicate records, noninvasive malignancies, precursor or benign hematologic conditions, skin cancers, in situ malignancies, or premalignant conditions. Abbreviations: CCC19, COVID-19 and Cancer Consortium; QS, quality score; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
current recommendation that IL6 inhibitors should be used with caution in immunocompromised patients [28].

Limitations of this study include retrospective data collection in many cases, potential ascertainment bias, limited granularity for specific pathogens and comorbid conditions, dependence on clinically annotated data with reliance on abstractor judgment, and use of time intervals rather than specific dates to ensure de-identified data. Also, we could not differentiate infections present at the time of COVID-19 diagnosis from nosocomial superinfections, which likely represent most coinfections among patients with COVID-19. We had no information regarding timing of corticosteroid administration as treatment for COVID-19 due to the survey design. Last, different and evolving institutional standards in diagnosing and reporting bacterial, viral, or fungal infections may account for the observed associations of coinfections with specific geographic regions and time periods.

While the above can be considered important limitations, this study represents a large multi-institutional effort subject to the realistic constraints of voluntary data reporting. Its strengths include the large number of patient records, allowing adjustments for multiple confounders, a comprehensive list of demographic, clinical, and laboratory variables, and a robust quality assurance process.

In conclusion, the frequency of coinfections among patients with cancer and COVID-19 in our study was relatively low but not trivial. Viral and fungal coinfections were uncommon. Coinfections were associated with high mortality rates. The use of tocilizumab in immunocompromised patients with cancer and COVID-19 may increase their risk of developing secondary infections. Several clinical and laboratory parameters could guide early empiric antimicrobial agent selection, which may improve clinical outcomes. These data could inform antimicrobial stewardship interventions in this tenuous patient population.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Table 3. Univariable and Adjusted Associations Between Coinfections and Mortality

| Coinfection, No. (%) | No Coinfection, No. (%) | Adjusteda OR (95% CI) | P Value |
|----------------------|-------------------------|-----------------------|---------|
| Any‡                 | 347/1459 (23.8)         | 669/7306 (9.4)        | 1.77 (1.50–2.08) | <.001 |
| Bacterial            | 261/1062 (24.6)         | 775/7703 (10.1)       | 1.61 (1.33–1.95) | <.001 |
| Viral                | 43/188 (22.9)           | 993/8577 (11.6)       | 1.48 (0.95–2.21) | .058  |
| Fungal               | 27/79 (34.2)            | 1009/8686 (11.6)      | 2.20 (1.28–3.76) | .004  |
| Not classified        | 136/563 (24.2)          | 900/8202 (11.0)       | 1.14 (0.89–1.47) | .293  |

Abbreviations: COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; HCT, hematopoietic cell transplant; OR, odds ratio.

‡Number with 30-day mortality/No. with yes/no coinfection (%).

†For age, sex, race, region, comorbidities (cardiovascular, pulmonary, renal disease, diabetes), ECOG Performance Status, type of malignancy, cancer status, HCT, recent cytotoxic chemotherapy, corticosteroids at any time, tocilizumab, period of COVID-19 diagnosis.

§The C-statistic of the model with any concomitant infection is 0.834.

Acknowledgments

We thank all members of the CCC19 steering committee, Tariq K. Choueiri, Narjus Duma, Dimitrios Farmakiotis, Petros Grivas, Gilberto de Lima Lopes Jr, Corrie A. Painter, Solange Peters, Brian I. Rini, Dimpy P. Shah, Michael A. Thompson, and Jeremy L. Warner, for their invaluable guidance of the COVID-19 and Cancer Consortium.

Financial support. H.K. has received a Bristol Myers Squibb Foundation Diversity In Clinical Trials Career Development Program grant (2021-2023); K.T.E. was supported by National Institute of General Medical Sciences of the National Institutes of Health (NIH) under award number T32GM007347; C.R.F. was supported by National Cancer Institute (NCI) of the NIH under award numbers T32CA236621 and P30CA046592. Dr. Choueiri is supported in part by the Dana-Farber/Harvard Cancer Centre Kidney SPORÉ (P50 CA101942) and P30 CA006516, both from NCI/NIH; the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, and Loker Pinard Funds for kidney Cancer Research at DFCI. Tianyi Sun and Drs. Mishra, French, and Warner: P30 CA068485 from NCI/NIH. Dr. Warner: U01 CA231840 from NCI/NIH. REDCap was developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). This study was partly supported by grants from the NCI (grant number P30 CA068485 to Vanderbilt University Medical Center). The funding sources had no role in writing of the manuscript or the decision to submit it for publication.

Potential conflicts of interest. Z.B. reports grants from imCORE/Genentech, non-financial support from Bristol Myers Squibb, and personal fees from UpToDate, outside the submitted work; B.B. reports other from Boehringer Ingelheim, other from Bicycle Therapeutics, other from Syros Pharmaceuticals, other from Amgen, other from Tarveda Therapeutics, other from KAHR Medical, and other from Ikenna Oncology, outside the submitted work; M.B. reports a research project that receives support from Merck, outside the submitted work; T.K.C. reports institutional and personal, paid and unpaid support for research, advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVIA, Ipsen, Kanaph, Lilly, Merck, Nikang, Novartis, Pfizer, Roche, Sanofi/Aventis, Takeda, Tempest, Up-To-Date, and CME events (Peerview, OncLive and others), outside the submitted work; A.E. reports salary support from the Canadian Institute of Health Research, the Royal College of Physicians and Surgeons of Canada (Detweiler Travelling Fellowship), and the Henry R. Shibata Fellowship, outside the submitted work; C.R.F. has received research support from the Merck Foundation and NCCN/Pfizer, unrelated to the current work; E.A.G. reports grants and personal fees from Genentech, personal fees from Alexion Pharmaceuticals, other from Apellis Pharmaceuticals, personal fees and other from Astex Pharmaceuticals, personal fees from Taiho Oncology, personal fees from Takeda Oncology, personal fees and nonfinancial support from Novartis Pharmaceuticals, grants and other from Celgene/BMS, and personal fees from CTI Biopharma, outside the submitted work; C.H. reports grants from Merck, grants from Bayer, grants from AstraZeneca, personal fees from Tempus, personal fees from EMD Serono, and other from Johnson and Johnson, outside the submitted work; A.K. reports other from TESARO, other from Halozyme, other from Geistlich Pharmaceuticals, other from Astellas Pharma, other from Rafael Pharmaceuticals, and other from OncLive, outside the submitted work; monies go to his institution for clinical trial from the named entities; V.S.K. has served in a consulting or advisory role for AstraZeneca, Clavis, Janssen, Pfizer, EMD Serono, Seattle Genetics/Astellas, Dendreon, Guidepoint, and GLG and has received research funding for the institution from Endocyte, Nektar, Clavis, Janssen, and Taiho; G.H.L. reports research funding from Amgen (Inst) and a speaking or advisory role for G1 Therapeutics, Partners Healthcare, BeyondSpring, Sandoz, Squibb (Inst), Merck, Jazz Pharm, Kalyope, TEVA, Fresenius Kabi, Seattle Genetics, and Samsung; R.R.M. has received research funding from Bayer, Pfizer, and Tempus; serves on the advisory board for AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Exelixis, Janssen, Merck, Novartis, Pfizer, Sanofi, and Tempus; is a consultant for Dendreon, Myovant, Sorrento Therapeutics, and Vividion; and serves on the molecular tumor board at Caris; R.N. reports personal fees from Promega, outside the submitted work; A.J.O. reports research funding for the institution from Genentech, TG Therapeutics, Genmab, Acrotech Biopharma, and Precision Bio and grants from Adaptive Biotechnologies and Foundation Medicine, outside the submitted work; O.A.P. reports personal fees from International Consulting Associates, Inc., outside the submitted work; S.M. reports personal fees from National Geographic for writing articles outside the submitted work; J.L.W. reports grants from NIH and AACR; personal fees from Westat, Roche, Melax Tech, and Flatiron Health; and equity in HemOnc.org LLC, outside the submitted work; D.F. has received research support from Astellas, Merck, and Viracor-Eufronis and consultant fees and honoraria from Viracor-Eufronis, outside the submitted work. All other authors: nothing to report. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Patient consent. This study was considered exempt from institutional review board (IRB) review at Vanderbilt University Medical Center (VUMC IRB 200467) and was approved by local IRBs at participating sites per institutional policy, according to the principles of the Declaration of Helsinki.

Trial registration. This study is registered on ClinicalTrials.gov, NCT04354701, and is ongoing.

References

1. World Health Organization. Weekly epidemiological update on COVID-19 - 6 January 2022. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-january-2022. Accessed 10 January 2022.

2. ElGohary GM, Hashmi S, Styczynski J, et al. The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther 2020; 5:1658-3876(20)30122-9.

3. Zhang H, Han H, He T, et al. Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2021; 113:371–80.
4. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020; 584:463–9.

5. Langford BJ, So M, Raywardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020; 26:1622–9.

6. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020; 2020; 81:266–75.

7. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020; 2020; 71:2459–68.

8. Granwehr BP, Kontoyiannis DP. The impact of infectious diseases consultation on oncology practice. Curr Opin Oncol 2013; 25:353–9.

9. Gudiol C, Durà-Miralles X, Aguilar-Company J, et al. Co-infections and superinfections complicating COVID-19 in cancer patients: a multicentre, international study. J Infect 2020; 2020; 81:266–75.

10. COVID-19 and Cancer Consortium. A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance. Cancer Cell 2020; 38:761–6.

11. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med 2021; 384:1503–16.

12. Zheng Y, Chen Y, Yu K, et al. Fatal infections among cancer patients: a population-based study in the United States. Infect Dis Ther 2021; 2021; 10:306–13.

13. Caillard S, Chavarot N, Francois H, et al. Is COVID-19 infection more severe in kidney transplant recipients? Am J Transplant 2021; 21:1295–303.

14. Saade A, Moratelli G, Dumas G, et al. Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect. Ann Intensive Care 2021; 11:83.

15. Grivas P, Khaki AR, Wise-Draper TM, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol 2021; 32:787–800.

16. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020; 395:1907–18.

17. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi (Basel) 2021; 7:298.

18. Fekkar A, Neofytos D, Nguyen M-H, Clancy CJ, Kontoyiannis DP, Lamothe F. COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it? J Infect Dis 2021; 27:1376–8.

19. Lamothe F, Lewis RE, Walsh TJ, Kontoyiannis DP. Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): a comparison with influenza associated aspergillosis (IAA). J Infect Dis 2021; doi:10.1093/infdis/jiab163.

20. Apostolopoulos A, Esquer Garrigos Z, Vijayvargiya P, Lerner AH, Farmakiotis D. Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: a systematic review of the literature. Diagnostics (Basel) 2020; 10:E807.

21. Flikweert AW, Grootenboers MJH, Yick DCY, et al. Late histopathologic characteristics of critically ill COVID-19 patients: different phenotypes without evidence of invasive aspergillosis, a case series. J Crit Care 2020; 59:149–55.

22. Kula BE, Clancy CJ, Hong Nguyen M, Schwartz IS. Invasive mould disease in fatal COVID-19: a systematic review of autopsies. Lancet Microbe 2021; 2:e405–14.

23. Freeman Weiss Z, Leon A, Koo S. The evolving landscape of fungal diagnostics, current and emerging microbiological approaches. J Fungi (Basel) 2021; 7:127.

24. White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis 2021; 73:e1634–44.

25. Permpalung N, Chiang TP-Y, Massie AB, et al. COVID-19 associated pulmonary aspergillosis in mechanically ventilated patients. Clin Infect Dis 2022; 74:83–91.

26. RECOVERY Collaborative Group; Horby P, Lim WS, Mathem M, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384:693–704.

27. Rivera DR, Peters S, Panagiotou OA, et al. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study. Cancer Discov 2020; 10:1514–27.

28. National Institutes of Health. Interleukin-6 inhibitors. Available at: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/interleukin-6-inhibitors/ Accessed 12 September 2021.